IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF

K. Kossen (Cambridge, United States of America), C. Schaefer (Cambridge, United States of America), S. Lim (Cambridge, United States of America), M. Michener (Cambridge, United States of America), P. Ruminiski (Cambridge, United States of America), D. Griggs (Cambridge, United States of America), R. Radhakrishnan (Cambridge, United States of America), B. Bradford (Cambridge, United States of America), S. Seiwert (Cambridge, United States of America)

Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Session: Translational aspects of idiopathic pulmonary fibrosis
Session type: Poster Discussion
Number: 5374
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Kossen (Cambridge, United States of America), C. Schaefer (Cambridge, United States of America), S. Lim (Cambridge, United States of America), M. Michener (Cambridge, United States of America), P. Ruminiski (Cambridge, United States of America), D. Griggs (Cambridge, United States of America), R. Radhakrishnan (Cambridge, United States of America), B. Bradford (Cambridge, United States of America), S. Seiwert (Cambridge, United States of America). IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF. 5374

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: